ArticleNature genetics2024
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Open access · hybridAbstract read
In one paragraph
Article in Nature genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
12.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC: A meta-analysis based on RCTs.Frontiers in oncology · 2026Pooled it
- FGFR4-associated APOBEC3 mutagenesis characterizes HER2-enriched subtype of human breast cancer.British journal of cancer · 2026Article
- Fc-Dependent Targeting of the GAS6-MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.Science advances · 2026Article
- Replication stress in cancer: origins, consequences and therapeutic opportunities.Nature reviews. Cancer · 2026Review
- Structure of full-length APOBEC3B bound to EBV BORF2 reveals coordinated neutralization of a cancer-associated mutator.Research square · 2026Article
- Distinct repair processes produce APOBEC-induced deletions, tandem substitutions, and complex mutations in yeast and human cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Evolution ofInternational journal of molecular sciences · 2026Review
- UNG-RPA interaction governs the choice between high-fidelity and mutagenic uracil repair.Nucleic acids research · 2026Article
- Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.JTO clinical and research reports · 2026Review
- Is cancer the result of uncontrolled cellular growth? a glance into the tumorigenic process.Cancer cell international · 2026Review
- Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- ApoFLARE: a luminescent reporter for direct quantification of APOBEC3A editing activity.bioRxiv : the preprint server for biology · 2026Article
- Challenges and advances in drug resistance and tolerance in cancer.Journal of experimental & clinical cancer research : CR · 2026Review
- RNA editing: an emerging frontier in cancer therapy - explorations, opportunities, and challenges.International journal of surgery (London, England) · 2026Article
- APOBEC3B/ASF1B-TGF-β signaling axis promotes epithelial-mesenchymal transition in HPV-positive oropharyngeal cancer.Journal of dental sciences · 2026Article
- Reprogramming tumor immunity through APOBEC3s-mediated mutagenesis: from genome instability to immune checkpoint interactions.Frontiers in immunology · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
85 authors at 18 institutions in 3 countries.
Deborah R Caswell *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. deborah.caswell@crick.ac.uk.ORCID 0000-0002-7550-5092
Philippe Gui *Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Manasi K Mayekar *Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Emily K LawDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-8867-7486
Oriol PichCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-1956-1882
Chris BaileyCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Jesse BoumelhaOncogene Biology Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-7635-2537
D Lucas KerrDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0557-8341
Collin M BlakelyDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8134-3651
Tadashi ManabeDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9891-5222
Carlos Martinez-RuizCancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.
Bjorn BakkerCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0003-3095-7287
Juan De Dios Palomino VillcasCore Research Laboratory, ISPRO, Florence, Italy.
Natalie I VokesDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3766-5335
Michelle DietzenCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-6853-7563
Mihaela AngelovaCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-0495-9695
Beatrice GiniDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6095-1500
Whitney TamakiDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1124-628X
Paul AllegakoenDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Wei WuDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6556-067X
Timothy J Humptonp53 and Metabolism Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-8030-9539
William HillCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Mona TomaschkoOncogene Biology Laboratory, The Francis Crick Institute, London, UK.
Wei-Ting LuCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-1405-4806
Franziska HaderkDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-0846-8332
Ai NaganoCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-2354-660X
Francisco Gimeno-ValienteCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.
Sophie de Carné TrécessonOncogene Biology Laboratory, The Francis Crick Institute, London, UK.
Roberto VendraminCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Vittorio BarbèCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Miriam MugaboCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.
Clare E WeedenCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Caroline E McCoachGenentech Inc, South San Francisco, CA, USA.
Bruna AlmeidaThe Roger Williams Institute of Hepatology, Foundation for Liver Research, London, UK.
Mary GreenExperimental Histopathology, The Francis Crick Institute, London, UK.
Carlos GomezDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Shigeki NanjoDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8356-9849
Dora BarbosaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Chris MooreOncogene Biology Laboratory, The Francis Crick Institute, London, UK.
Joanna PrzewrockaCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
James R M BlackCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-5598-7752
Eva GrönroosCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-8303-5409
Alejandro Suarez-BonnetExperimental Histopathology, The Francis Crick Institute, London, UK.ORCID 0000-0003-0296-5896
Simon L PriestnallExperimental Histopathology, The Francis Crick Institute, London, UK.ORCID 0000-0002-6027-1879
Caroline ZverevBiological Research Facility, The Francis Crick Institute, London, UK.
Scott LighternessBiological Research Facility, The Francis Crick Institute, London, UK.
James CormackBiological Research Facility, The Francis Crick Institute, London, UK.
Victor OlivasDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Lauren CechDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3621-4129
Trisha AndrewsDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Brandon RuleCursorless, London, UK.ORCID 0000-0002-0757-5363
Yuwei JiaoNovogene Europe, Cambridge, UK.
Xinzhu ZhangNovogene Europe, Cambridge, UK.
Paul AshfordInstitute of Structural and Molecular Biology, University College London, London, UK.ORCID 0000-0003-4079-0257
Cameron DurfeeDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID 0000-0002-8130-4270
Subramanian VenkatesanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Nuri Alpay TemizInstitute for Health Informatics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-1416-3639
Lisa TanDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Lindsay K LarsonDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Prokopios P ArgyrisDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
William L BrownDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-5354-9468
Elizabeth A YuDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Julia K RotowLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Udayan GuhaThoracic and GI Malignancies Branch, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0003-1087-9218
Nitin RoperDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Johnny YuBiomedical Sciences Program, University of California, San Francisco, San Francisco, CA, USA.
Rachel I VogelDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-0149-8464
Nicholas J ThomasDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4931-4716
Antonio MarraDivision of Early Drug Development for Innovative Therapy, European Institute of Oncology IRCCS, Milan, Italy.
Pier SelenicaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Helena YuMemorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID 0000-0002-0377-9510
Samuel F BakhoumHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Su Kit ChewCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID 0000-0003-2969-3173
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.ORCID 0000-0003-1212-1259
Karen H Vousdenp53 and Metabolism Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-7365-1766
Nicholas McGranahanCancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0201-4444
Nnennaya KanuCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID 0000-0002-9034-9112
Julian DownwardOncogene Biology Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-2331-4729
Trever G BivonaDepartments of Medicine and Cellular and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.ORCID 0000-0001-5734-4128
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-4299-3018
The Francis Crick Institute · GBUniversity of California, San Francisco · USUniversity of Minnesota · USCancer Research UK · GBMemorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USNational Institutes of Health · USNeogen Europe (United Kingdom) · GBRoyal Veterinary College · GBEuropean Institute of Oncology · ITGlasgow Caledonian University · GBHoward Hughes Medical Institute · USInstitute of Structural and Molecular Biology · GBKing's College London · GBRoyal London Hospital · GBSutter Health · USThe University of Texas Health Science Center at San Antonio · USThe University of Texas MD Anderson Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMUTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007185 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle, LAURENCE HUANG · 1985 to 2026
$24.6MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3MPROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Reuben S Harris · 2019 to 2026
$14.5MUCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona, Jack Roth · 2017 to 2026
$12.9MThe Cancer Target Discovery and Development Network at UCSFU01CA217882 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANDYOPADHYAY, SOURAV, BIVONA, TREVER G · 2017 to 2021
$5.2MCharacterization of YAP as a rational companion target in lung cancerR01CA204302 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona · 2017 to 2026
$3.7MRational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer TreatmentR01CA169338 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2013 to 2023
$3.4MGenomics and Functional Characterization of NF1-mutated Lung CancerR01CA227807 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2018 to 2022
$2.8MDrivers of histologic transformation in EGFR-mutant lung cancerR01CA264078 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RUDIN, CHARLES M., YU, HELENA · 2021 to 2025
$2.0MOptimizing biologically-based rational polytherapy in ALK+ lung cancerR01CA211052 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2017 to 2021
$1.8MAn Interdisciplinary Training Program to Transform Graduate Education In Genetics and GenomicsT32GM140936 · NIGMS · UNIVERSITY OF MINNESOTA · PI ALBERT, FRANK WOLFGANG, GREENSTEIN, DAVID IRWIN · 2021 to 2025
$851kCancer Research UK 17786Cancer Research UK 21999Cancer Research UK 30025NCI NIH HHS P01 CA234228NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA169338NCI NIH HHS R01 CA204302NCI NIH HHS R01 CA211052NCI NIH HHS R01 CA227807NCI NIH HHS R01 CA264078NCI NIH HHS U01 CA217882NCI NIH HHS U54 CA224081NHLBI NIH HHS T32 HL007185NIGMS NIH HHS T32 GM140936Wellcome Trust CC2041Wellcome Trust FC001169
Abstract
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsCytidine DeaminaseErbB ReceptorsHumansMiceMinor Histocompatibility AntigensMutationUp-RegulationAPOBEC3B protein, humanCytidine DeaminaseErbB ReceptorsMinor Histocompatibility Antigens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.